Atorvastatin administration is associated with dose-related changes in IGF bioavailability

Short title:
IGF levels after atorvastatin therapy

Authors and affiliations:
Ram P Narayanan MRCP 1; Matthew Gittins MSc 2; Kirk W Siddals PhD 1; Robert L Oliver PhD 1; Julie E Hudson MSc 1; Anne White PhD, FSB 3; Paul Durrington MD FMedSci 4; Robert R Davies FRCP 5; Martin K Rutter* MD, FRCP 3,5; J Martin Gibson* MD, PhD, FRCP 1

MKR and JMG share joint last authorship

1 Vascular Research Group, The University of Manchester, Clinical Sciences Building, Salford Royal Hospital NHS Foundation Trust, Salford M6 8HD, United Kingdom

2 Department of Statistics, School of Medicine, The University of Manchester, Oxford Road, Manchester M13 9PL, United Kingdom

3 Endocrinology and Diabetes Group, Faculty of Medical, Human and Life Sciences, The University of Manchester, Oxford Road, Manchester M13 9PT, United Kingdom

4 Cardiovascular Research Group, The University of Manchester, Manchester M13 9NT, United Kingdom

5 Manchester Diabetes Centre, Central Manchester University Hospital NHS Foundation Trust, Manchester M13 0JE, United Kingdom

Corresponding author details:
Dr. Ram Prakash Narayanan, B-202, Clinical Sciences Building, Salford Royal Hospital NHS Foundation Trust,
Clinical trial registration: ISRCTN 58196433 (www.controlled-trials.com)

Key words: statins, insulin-like growth factors, diabetes mellitus, bioavailability, dose-related
Objective: Insulin-like growth factor (IGF) levels, their binding proteins (IGFBPs), and high-dose statin therapy, have all been linked to the development of diabetes. We aimed to identify whether atorvastatin caused dose-related changes in IGF proteins.

Design and methods: We measured IGF1, IGF2, IGFBP1 and IGFBP3 concentrations at baseline, 6 months and 12 months in PANDA trial participants with type 2 diabetes randomised to 10mg (n=59) vs 80mg (n=60) of atorvastatin (N=119; mean (SD): age 64(10) years; 83% male; HbA1c 61(10) mmol/mol; blood pressure 131/73 mmHg.

Results: Atorvastatin was associated with overall reductions in circulating IGF1, IGF2 and IGFBP3 concentrations (p<0.05 for all changes). The adjusted mean (95% CI) between-group differences that indicate dose-related changes in IGF proteins were not significant for: IGF1: -3 (-21 to 14) ng/ml; IGF2: -23 (-65 to 18) ng/ml; and IGFBP3: -0.34 (-0.71 to 0.03) µg/ml; negative values indicating numerically greater lowering with high-dose). The IGFBP1 concentration did not change overall with atorvastatin therapy overall but the adjusted mean (95% CI) between-group difference indicating a dose-related change in log IGFBP1 was highly significant -0.41 (-0.69 to 0-0.13, p=0.004).

Conclusion: IGF1, IGF2 and IGFBP3 concentrations all decreased following atorvastatin therapy. A differential effect of low vs high dose atorvastatin on IGFBP1 concentrations was observed with likely implications for IGF bioavailability. The dose-related differential impact of atorvastatin treatment on concentration of IGF proteins merits investigation as a mechanism to explain the worsening of glucose tolerance with statin therapy.
INTRODUCTION

3-Hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) have an established role in the prevention of cardiovascular disease\(^1\). However recent studies suggest that high dose statin therapy may be associated with a small but significant increase in the risk of type 2 diabetes through unknown mechanisms\(^2\). The ligands IGF1 and IGF2 have structural and functional homologies with insulin, and their downstream signalling pathways have many commonalities with that of insulin\(^3\). Low IGF1 concentration has been linked with increased rates of glucose intolerance and type 2 diabetes\(^4,6\), though there are some suggestions that high IGF1 levels may also be related to an increase in diabetes incidence\(^7\). Polymorphisms in the *IGF1* gene have been associated with fasting insulin in genome-wide association studies\(^8\).

IGF2 is critical in embryonic growth and development but its post-natal roles are less clear. IGF2 signalling can occur through the insulin receptors, and excessive IGF2 production in neoplasms is known to cause hypoglycaemia\(^9\).

IGFBP1 is an acute modulator of IGF1 and IGF2 bioavailability, and altered IGFBP1 levels have also been linked to diabetes rates\(^10,12\). IGF binding protein-3 is the principal carrier protein of IGF1 and IGF2. *In vitro* studies suggest that statins have profound effects on insulin and IGF1 signalling\(^13\). The aim of our study was to identify dose-related changes in the circulating levels of insulin-like growth factors and their major binding proteins with statin therapy in patients with type 2 diabetes.

MATERIALS AND METHODS

Subjects:

We studied individuals in the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) study that has been previously described\(^14\). Briefly, participants were > 40 years of age with type 2 diabetes and microalbuminuria recruited from four secondary care based diabetes clinics in Manchester, UK. Exclusion criteria included: pregnancy; proteinuria > 2g per day; serum creatinine > 200µmol/L; blood pressure > 160/90 mm Hg at randomisation; serum cholesterol > 7...
mmol/L; abnormal liver function; HbA1c > 86 mmol/mol (10%); untreated hypothyroidism; intolerance of statin or angiotensin II receptor blocking drugs; subjects taking atorvastatin doses > 10 mg daily or the equivalent doses of other statins; use of any non-statin lipid lowering agent or the presence of any illness that could affect the trial.

After a statin washout period of up to two weeks duration, patients were randomised to either 10 mg or 80 mg (2x40 mg tablets) atorvastatin including matching placebo tablets in a double blind fashion. Placebo tablets were used so that patients in the low-dose and high-dose groups received the same number of identical tablets.

The study was approved by the local research ethics committee, informed consent was obtained from all patients and investigations were carried out in accordance with the principles of the Declaration of Helsinki as revised in 2000.

Laboratory Measurements:

Analysis of fasting IGF1, IGF2, IGFBP1 and IGFBP3 was performed on blood samples drawn at baseline, 6 months and twelve months. Plasma IGF1 and IGFBP3 were measured using an Immulite 1000 Immunoassay system (Siemens Healthcare Diagnostics Inc, Tarrytown, NY), utilising an enzyme-labelled chemiluminescent immunometric assay. Serum IGF2 was measured using a locally developed two-site extraction based enzyme-linked immunosorbent assay using antibodies that have been previously reported. Plasma IGFBP1 was measured using a locally developed two site ELISA that can detect all phospho-isoforms of this protein. Monoclonal antibodies 6301 (capture antibody) and 6303 (detection antibody) were obtained from Medix Biochemica (Kaunianen, Finland). The analytical sensitivities, inter-assay and intra-assay coefficients of variation for the assays were: IGF1: 20 ng/ml, <8.4%, <4.5%; IGF2: 5 ng/ml, <9.2%, <9.2%; IGFBP1: 0.1 ng/ml, <7%, <9.4%; IGFBP3: 0.1 µg/L, <10% and <6%.

Statistical Analyses:
A log-transformation of the skewed IGFBP1 values meant that assumptions of normality were maintained and parametric tests were used throughout. In order to estimate for IGF1 bioavailability, molar ratios of IGF1:IGFBP1 and IGF1:IGFBP3 were included in their analysis. Unadjusted mean (95% CI) within-individual change from baseline to 12 months in IGF1, IGF2 and the binding protein levels were calculated for high- and low-dose atorvastatin groups (figure 1). The main end-point of the study was the differential effects of high-dose versus low-dose atorvastatin on concentrations of plasma IGF1, serum IGF2, plasma IGFBP1 and plasma IGFBP3 over a 12 month period. A linear mixed-effects model was used to calculate the effect of atorvastatin dose (10mg vs 80mg) on circulating levels of the four IGF proteins across longitudinal data collected at approximately 6 months and 12 months. In each analysis, these levels were adjusted for the following covariates defined *a priori*: mean centred time, age, gender, baseline measurements of the IGF proteins, body-mass index (BMI) and the use of insulin and statins prior to randomization. In each case, an interaction term, mean centred time and atorvastatin dose with respect to any of the proteins measured, was found to be non-significant and removed from the model. Accordingly the analysis was configured to identify the differential impact of the 80 mg dose of atorvastatin as compared to the 10 mg dose on each of the IGF proteins. All analyses were performed using Stata 11 (Statacorp., College Station, TX). Two-tailed p<0.05 was considered statistically significant.

**RESULTS**

Clinical characteristics of the study population at randomisation are shown in table 1. As previously described, those randomised to high- versus low-dose atorvastatin were similar with respect to age, gender, microalbuminuria, hypertension and glycaemic control at randomization\(^{14}\). A high proportion of participants in both the high- and low-dose atorvastatin study groups had a statin washout period that was up to two weeks in duration. We excluded one subject from analysis who had biologically implausible results.

The baseline concentrations of the IGF proteins in the high- and low-dose treatment groups are shown in table 2 (columns 2 and 3), and the changes in each of these at 6 months and 12 months is shown in
figure 1. Atorvastatin therapy was associated with significant reductions in circulating levels of IGF1, IGF2 and IGFBP3 when groups taking low-dose and high-dose atorvastatin were combined. The unadjusted mean (95% CI) change in IGF proteins for combined low- and high-dose atorvastatin groups were: IGF1: -22 (-35 to -10) ng/ml; IGF2: -46 (-75 to -16) ng/ml, and IGFBP3: -1.0 (-1.3 to -0.7) mg/L (p<0.05 for all changes; table 2). The corresponding data for IGFBP1 were: 5 (-19 to 29) ng/ml, p=NS. The concentration of IGFBP1 was reduced in subjects receiving high-dose atorvastatin, but was increased from baseline with low-dose therapy (figure 1). However, we did not assess the statistical significance of within-group changes because the results may have been misleading due to the absence of a placebo-only-treated group.

Table 2 (columns 5 and 6) shows the results of the mixed-effects longitudinal model in which between-group differences over 12 months were adjusted for baseline levels of each biomarker, age, sex, body-mass index and the use of statin washout period and use of insulin therapy at baseline. The adjusted mean (95% CI) between-group difference in log-IGFBP1 was highly significant (-0.41(-0.69 to -0.13), p=0.004). In these analyses negative values indicate numerically higher lowering of IGF values with 80 mg dose as compared to the 10 mg dose. The corresponding data for IGFBP1 without log-transformation was also statistically significant (adjusted mean (95% CI) between-group difference in IGFBP1: -37 (-68 to -6), p=0.02). This data is presented in table 2 for comparison with other unadjusted data (ie. not adjusted for baseline levels of each biomarker, age, sex, body-mass index and the use of statin washout period and use of insulin therapy at baseline). There was a corresponding significant increase in IGF1/IGFBP1 ratio: mean (95% CI) : 7(1 to 12), p=0.02. Here, a positive value indicates that subjects on 80 mg atorvastatin had higher mean IGF1/IGFBP1 ratio values during follow-up as compared to subjects on the 10 mg dose of atorvastatin.

The adjusted mean (95% CI) between group difference in IGF proteins between the high-dose and low-dose atorvastatin treatment groups was not significant for IGF1 (-3(-20 to 14)), IGF2 (-23(-65 to 18)) and IGFBP3 (-0.34(-0.71 to 0.03)).
There was no correlation between change in HbA1c and IGFBP1 (or any of the other measured IGF proteins) over the 12 month period of this study.

**DISCUSSION**

Here we present the first study demonstrating the effects of different statin doses on longitudinal trends in insulin-like growth factors and their binding proteins. The observed changes are important because changes in IGF bioavailability have known associations with diabetes incidence, and higher rates of incident diabetes have been observed with high-dose statin therapy.  

**Main findings**

We showed that atorvastatin therapy overall (low dose and high dose atorvastatin combined) was associated with a decrease in IGF1, IGF2 and IGFBP3 levels. We have also demonstrated a dose-dependent effect of atorvastatin on plasma IGFBP1 concentration. Low-dose atorvastatin therapy increased IGFBP1 levels, while high-dose treatment resulted in a fall.

**IGFBP1 system in health and disease**

Insulin-like growth factors IGF1 and IGF2 are potent anabolic factors that are fundamental to growth, development and metabolism. Both peptides have significant structural homology with insulin and share similar downstream signalling pathways, suggesting a role in glucose homeostasis. The biological actions of IGF1 and IGF2 are determined by their interactions with six binding proteins, described as IGF binding proteins 1 to 6 (IGFBP1 to IGFBP-6). Insulin-like growth factor binding protein-1 (IGFBP1) is the principal acute regulator of IGF1 biological actions. IGFBP1 is potently and dynamically inhibited by insulin, and levels are affected by the diet and prandial state as well as other factors like age and body-mass index.

IGFBP1 is a marker of insulin sensitivity. In clinical and population studies, low circulating IGFBP1 concentration has been associated with insulin resistance, and an increased risk for incident gestational diabetes, glucose intolerance and type 2 diabetes.
Recent meta-analyses have suggested that, when compared to placebo, statin therapy was associated with a 9% higher risk for incident diabetes\textsuperscript{21}, and when compared to low dose statin therapy, high dose statin therapy was associated with a further 12% elevation in risk\textsuperscript{2}. There is also evidence that statin therapy is associated with worsening glycaemic control in individuals who already have type 2 diabetes\textsuperscript{24}. On a cellular level we have previously shown that statins can directly reduce insulin signalling by depleting cells of dolichol, a derivative of mevalonate, which in turn affects insulin receptor processing with the eventual result of fewer, mature, insulin receptors at the cell surface\textsuperscript{13}. In the present study which involved individuals with type 2 diabetes, an exploratory analysis did show that high dose atorvastatin was associated with worse glycaemic control at the 2-year follow-up (HbA\textsubscript{1c} was 2.4 mmol/l (0.3%) higher (p=0.017) after 2 years of high-dose therapy\textsuperscript{14}, but these differences were not significant at 1 year (not shown).

We showed that compared to the low-dose therapy, high dose atorvastatin was associated with lowering of IGFBP1 levels, which has been associated with an increased risk for gestational diabetes, glucose tolerance and type 2 diabetes\textsuperscript{4, 11, 22, 25, 26}. The cause of the dose-dependent effect of atorvastatin on IGFBP1 concentration is unclear. However since a dose-dependent effect of atorvastatin on insulin resistance has been described\textsuperscript{27}, it is tempting to speculate that changes in insulin concentration and insulin resistance may be implicated. If high-dose atorvastatin caused greater insulin resistance and hyperinsulinaemia as compared to low dose atorvastatin, then this could suppress hepatic IGFBP1 production and decrease circulating IGFBP1 concentration. Since we did not measure insulin levels, we are unable to test this hypothesis.

**Effect on other IGF proteins and implications for diabetes risk**

The majority of our patients had a two-week statin washout period that was up to 2-weeks in duration. This may have been long enough to allow IGF proteins to return towards normal pre-treatment levels. In our within-group analysis, we showed longitudinal reductions in IGF1, IGF2 and IGFBP3 with both low- and high-dose atorvastatin therapy. The design of our trial means that these data are less
robust than our comparison of the low- and high-dose atorvastatin groups. However these data are in
keeping with the results of a study involving 156 patients with hypercholesterolaemia who
experienced lowering of IGF1 levels with low dose simvastatin therapy\textsuperscript{28}. Although we showed that
the effect on these protein concentrations was not dose-dependent, the overall fall in insulin-like
activity resulting from lower IGF1 and IGF2 concentration could potentially contribute to increased
glucose concentrations, perhaps partly mediated by a compensatory elevation in growth hormone. The
changes in IGF proteins might go some way to explain the increased risk of incident diabetes in
patients receiving statin therapy compared to placebo\textsuperscript{23}.

\textit{Effect on other IGF proteins and implications for cardiovascular and malignancy risk}

Altered concentrations of insulin-like growth factor proteins have been associated not only with
subsequent worsening of glucose tolerance but also increased macrovascular risk\textsuperscript{4, 12, 29, 30}. However,
statin therapy unambiguously decreases cardiovascular risk, suggesting that associations of low IGF
bioavailability with an adverse cardiovascular profile are not sustained in the presence of statin
therapy. Arguably, the cardiovascular benefits of atorvastatin therapy would be even greater without
the increased incidence of diabetes.

\textit{Strengths and weaknesses}

This is the first study to demonstrate dose-dependent effects of a statin on insulin-like growth factors
and two binding proteins that influence IGF bioavailability. The data is particularly valuable because
the patients were well-characterised and were involved in a randomised double-blind placebo-
controlled clinical trial comparing the clinical effects of different statin doses. The study does have
some weaknesses. First, it was a relatively small study with a short duration of follow-up but
nevertheless we were able to show dose-dependent effects of atorvastatin on the IGF system.
However, the limited sample size may explain the lack of significant correlation between changes in
IGFBP1 and HbA\textsubscript{1c}. Second, although the study was designed prospectively, this was a \textit{post hoc}
analysis of a trial designed for another purpose-i.e. to assess the effects of statin dose on renal
function. Third, this was a study of patients with type 2 diabetes and albuminuria and therefore the
results may have limited generalizability. Fourth, we did not measure glucose tolerance or insulin resistance which would have helped clarify the underlying pathophysiological mechanisms. Lastly, we performed the study in patients with type 2 diabetes and therefore we were not able to relate changes in IGF proteins to incident diabetes.

Clinical implications and future work

There are no immediate clinical implications of this work, but this is an important area for future research because of the increasing and widespread use of statin medication. Although statins have major health benefits, there is a need to understand the mechanisms behind potential adverse effects so that we might develop ways to mitigate these effects. Our study needs to be replicated in larger and more diverse populations in the first instance.

We report an overall decrease in the concentration of the insulin-like growth factors with atorvastatin therapy, and a dose-dependent change in IGFBP1 concentration following atorvastatin administration in patients with type 2 diabetes. The effects of atorvastatin on IGF1, IGF2, IGFBP1 and IGFBP3 concentration could suggest a possible mechanism linking high-dose 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitor treatment with higher rates of incident type 2 diabetes.

DECLARATION OF INTEREST

JMG and MKR have received travel grants and honoraria for speaking at meetings sponsored by Pfizer. MG’s salary has previously been partly funded by research grants from Pfizer. The University and Hospital trusts employing MKR and JMG have received research grants from Pfizer UK. The authors report no other conflicts of interest.

FUNDING

The PANDA study was funded by an unrestricted grant from Pfizer UK which markets atorvastatin. The sponsors were allowed to comment on the manuscript but they had no right of veto over any of the contents.
ACKNOWLEDGEMENTS

This study was supported by the Manchester Academic Health Science Centre (MAHSC) and the Manchester NIHR Biomedical Research Centre. MKR is supported by a HEFCE Clinical Senior Lecturer award.

The online version of this manuscript contains an additional table (Table 3) that represents the mean circulating concentrations of IGF1, IGF2, IGFBP1 and IGFBP3 at study baseline, 6 months and at study completion (12 months) for study subjects administered 10mg of atorvastatin, 80 mg atorvastatin and for the study population as a whole.

REFERENCES


MR, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Fox CS, Frants R, Franzosi MG, Galan P,

Goodarzi MO, Graessler J, Groves CJ, Grundy S, Gyllensten U, Hadjadj S,


Hercberg S, Herder C, Hicks AA, Hillman DR, Hingorani AD, Hofman A, Hui J, Hung J, Isomaa

B, Johnson PRV, Jorgensen T, Jula A, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimaki M, Knight


Lyssenko V, Mahley R, Mangino M, Manning AK, Martinez-Larrad MT, McCance A, McCarron T,

McCulloch L, McPherson R, Meisinger C, Melzer D, Meyre D, Mitchell BD, Morken MA,

Mukherjee S, Naitza S, Narisu N, Neville MJ, Oostra BA, Orru M, Pakyz R, Palmer C, Nalls MA,

Paolisso G, Pattaro C, Pearson D, Pedersen NL, Perola M, Planche AF, Pichler I,

Polasek O, Posthuma D, Potter SC, Pouta A, Province MA, Psaty BM, Rathmann W, Rayner


T, Thorand B, Tichert J, Tonjes A, Tuomilehto J, Uitterlinden AG, van Dijk KW, van Hoek M, Varma


KL, Watkins H, Weeden MN, Wild SH, Willemsen G, Witteman JCM, Yarnell JW, Zeggini E,


AT, Silander K, Salomaa V, Smith GD, Bornstein SR, Schwarz P, Sjogren J, Karpe F, Shuldiner

AR, Cooper C, Dedoussis GV, Serrano-Rios M, Morris AD, Lind L, Palmer LJ, Hu FB, Franks PW,

Ebrahimi S, Mathers M, Kao WHL, Pouta A, Province K, Sampson MJ, Kuksisto J, Laaoko M, Hansen T,

Pedersen O, Pramstaller PP, Wichmann HE, Illig T, Rudan I, Wright AF, Stumvoll M, Campbell

H, Wilson JF, Anders Hamsten on behalf of Procardis C, Investigators M, Bergman RN,

Buchan TA, Collins FS, Mohlke KL, Tuomilehto J, Valle TT, Alshuler D, Rotter JI, Siscovick

DS, Penninx BWJH, Boomsma DI, Deloukas P, Spector TD, Frayling TM, Ferrucci, L, Kong A,

Thorsteinsdotir U, Stefansson K, van Duijn CM, Aulchenko YS, Cao A, Scuteri A, Schlessinger


V, Abecasis GR, Wareham NJ, Sladek R, Froguel P, Watanabe RM, Meigs JB, Groop L,

Boehnke M, McCarthy MI, Flores JC & Barroso I. New genetic loci implicated in fasting

glucose homeostasis and their impact on type 2 diabetes risk. Nature Genetics 2010 42 105-

116.


10. Petersson U, Ostgren CJ, Brudin L, Brismar K & Nilsson PM. Low levels of insulin-like growth-
factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2

diabetes and impaired glucose tolerance (IGT): the Soderakra Cardiovascular Risk Factor

Study. Diabetes & Metabolism 2009 35 198-205.

11. Lewitt MS, Hilding A, Ostenson CG, Efendic S, Brismar K & Hall K. Insulin-like growth factor-

binding protein-1 in the prediction and development of type 2 diabetes in middle-aged


Fraser W, White A & Gibson JM. Close relation of fasting insulin-like growth factor binding

protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations.

Diabetologia 2001 44 333-339.


factor-1 (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein

prenylation and receptor glycosylation pathways. Journal of Biological Chemistry 2004 279

38353-38359.

14. Rutter MK, Prins HR, Charlton Menys V, Gittins M, Roberts C, Davies RR, Moorhouse A,

Jinadev P, France M, Wiles PG, Gibson JM, Dean J, Kalra PA, Cruickshank JK & Durrington PN.
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). *Diabetic Medicine* 2011 28 100-108.


Figure 1. Mean change in IGF1, IGF2, IGFBP1 and IGFBP3 concentrations from baseline in subjects treated with 10mg and 80mg of atorvastatin
Table 1: Baseline clinical characteristics at randomisation by treatment group

<table>
<thead>
<tr>
<th>Baseline characteristic</th>
<th>Atorvastatin 10 mg</th>
<th>Atorvastatin 80 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>59</td>
<td>60</td>
</tr>
<tr>
<td>Age (years)</td>
<td>65 (10)</td>
<td>63.5 (9.5)</td>
</tr>
<tr>
<td>Male (%)</td>
<td>81</td>
<td>85</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>98</td>
<td>96</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td>12.6 (8.7)</td>
<td>11.1 (7.8)</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>32 (29-35)</td>
<td>34 (28-38)</td>
</tr>
<tr>
<td>Diabetes therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral hypoglycaemic agents (%)</td>
<td>48</td>
<td>40</td>
</tr>
<tr>
<td>Insulin only (%)</td>
<td>14</td>
<td>10</td>
</tr>
<tr>
<td>Insulin and OHA (%)</td>
<td>32</td>
<td>43</td>
</tr>
<tr>
<td>MDRD eGFR (mL/min/1.73 m(^2))</td>
<td>61 (44-76)</td>
<td>72 (54-85)</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>5.1 (1.0)</td>
<td>5.2 (1.1)</td>
</tr>
<tr>
<td>HbA(_{1c}) (%)</td>
<td>7.8 (1.2)</td>
<td>7.6 (1.4)</td>
</tr>
<tr>
<td>HbA(_{1c}) (mmol/mol)</td>
<td>62 (10)</td>
<td>60 (8)</td>
</tr>
<tr>
<td>Statin washout period of up to 2 weeks (%)</td>
<td>90</td>
<td>97</td>
</tr>
</tbody>
</table>

Data are mean (SD) or %, unless stated.
BMI= body mass index; HbA\(_{1c}\), glycated haemoglobin; MDRD eGFR, Modification of diet in renal disease estimated glomerular filtration rate; OHA, oral hypoglycaemic agents
Hypertension was defined as BP>130/80 mmHg or anti-hypertensive therapy
Table 2: IGF endpoints: Baseline data, unadjusted 12-month change for combined groups and adjusted mean (95% CI) differences between high- and low-dose atorvastatin groups over the 12 month follow-up period.

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Baseline value in Atorvastatin 10 mg daily group (N=59)</th>
<th>Baseline value in Atorvastatin 80 mg daily group (N=60)</th>
<th>Unadjusted mean (95% CI) change between final visit and baseline for all patients (10 mg and 80 mg/day groups combined)</th>
<th>Adjusted mean (95% CI) difference between high- and low-dose groups over 12 months of follow-up</th>
<th>P-value for adjusted mean difference between groups during follow-up, adjusted for baseline differences</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGF1 (ng/ml)</td>
<td>154 (61)</td>
<td>152 (62)</td>
<td>-22 (-35 to -10)*</td>
<td>-3 (-20 to 14)</td>
<td>0.72</td>
</tr>
<tr>
<td>IGF2 (ng/ml)</td>
<td>461 (156)</td>
<td>504 (165)</td>
<td>-46 (-75 to -16)*</td>
<td>-23 (-65 to 18)</td>
<td>0.27</td>
</tr>
<tr>
<td>IGFBP1 (ng/ml)</td>
<td>74 (29 to 142)</td>
<td>54 (32 to 113)</td>
<td>5 (-19 to 29)</td>
<td>-37 (-68 to -6)</td>
<td>0.02</td>
</tr>
<tr>
<td>IGFBP3 (mg/L)</td>
<td>4.5 (1.4)</td>
<td>4.9 (1.7)</td>
<td>-1.0 (-1.3 to -0.7)*</td>
<td>-0.34 (-0.71 to 0.03)</td>
<td>0.07</td>
</tr>
<tr>
<td>IGF1/IGFBP1</td>
<td>14 (16)</td>
<td>17 (31)</td>
<td>0 (-5 to 4)</td>
<td>7 (1 to 12)</td>
<td>0.02</td>
</tr>
<tr>
<td>IGF1/IGFBP3</td>
<td>0.2 (0.06)</td>
<td>0.2 (0.06)</td>
<td>0.01 (-0.00 to 0.02)</td>
<td>0.01 (-0.01 to 0.02)</td>
<td>0.48</td>
</tr>
</tbody>
</table>

Baseline data are mean (SD) or median (IQR). *P<0.05.
Change and difference data are mean (95% CI) values. Data are adjusted for baseline level of IGF molecule, age, sex, body mass index, use of insulin therapy, and use of a washout period. A negative value for adjusted mean difference indicates that patients receiving atorvastatin 80 mg daily had lower average values during follow-up than those receiving 10 mg daily. For example, IGF-1 levels were 3 mmol/L lower (p=0.72) during follow-up in patients taking atorvastatin 80 mg daily compared to those taking 10 mg daily. A positive value for adjusted mean difference indicates that patients receiving atorvastatin 80 mg daily had higher average values during follow-up than those receiving 10 mg daily.

The number of patient samples available for each analysis: 10 mg daily dose: 50-52 patients; 80 mg daily dose 50-51 patients. Mean (inter-quartile range) follow-up was 12.0 (11.7-12.4) months.
Table 3: Mean (SD) concentrations of plasma IGF1, IGFBP1, IGFBP3 and serum IGF2 at baseline, 6 months and 12 months in the PANDA trial

<table>
<thead>
<tr>
<th>Visit</th>
<th>10 mg</th>
<th>80 mg</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IGF1</td>
<td>IGF2</td>
<td>IGFBP1</td>
</tr>
<tr>
<td></td>
<td>(ng/ml)</td>
<td>(ng/ml)</td>
<td>(mg/ml)</td>
</tr>
<tr>
<td>Baseline</td>
<td>N</td>
<td>53</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>157.4</td>
<td>461</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>66.0</td>
<td>155</td>
</tr>
<tr>
<td>6 mths</td>
<td>N</td>
<td>55</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>140.9</td>
<td>455</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>55.8</td>
<td>148</td>
</tr>
<tr>
<td>12 mths</td>
<td>N</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>125.9</td>
<td>445</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>40.4</td>
<td>149</td>
</tr>
</tbody>
</table>

N indicates number of subjects with valid measurements of IGF proteins at each time point. Reductions in mean concentrations of plasma IGF1, serum IGF2 and plasma IGFBP3 at study completion (12 months) as compared to baseline were statistically significant (p<0.05) for the study population as a whole.
Figure 1.
Mean change in IGF1, IGF2, IGFBP1 and IGFBP3 concentrations from baseline in subjects treated with 10mg and 80mg of atorvastatin
215x156mm (96 x 96 DPI)